Aurinia Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Aurinia Pharmaceuticals
AUPH Stock  USD 7.95  0.05  0.62%   
Aurinia Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Aurinia Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aurinia Pharmaceuticals financial statements helps investors assess Aurinia Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aurinia Pharmaceuticals' valuation are summarized below:
Gross Profit
169.4 M
Profit Margin
(0.10)
Market Capitalization
1.1 B
Enterprise Value Revenue
4.014
Revenue
220.4 M
We have found one hundred twenty available fundamental signals for Aurinia Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Aurinia Pharmaceuticals prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The Aurinia Pharmaceuticals' current Market Cap is estimated to increase to about 1.8 B. The Aurinia Pharmaceuticals' current Enterprise Value is estimated to increase to about 1.5 B

Aurinia Pharmaceuticals Total Revenue

211.93 Million

Check Aurinia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aurinia Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.1 M, Interest Expense of 3.4 M or Selling General Administrative of 235.5 M, as well as many indicators such as Price To Sales Ratio of 6.27, Dividend Yield of 0.0 or PTB Ratio of 3.22. Aurinia financial statements analysis is a perfect complement when working with Aurinia Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Aurinia Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

Aurinia Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets661.8 M630.3 M260.4 M
Slightly volatile
Short and Long Term Debt Total117.9 M112.2 M25.8 M
Slightly volatile
Other Current Liabilities62.5 M59.6 M17.7 M
Slightly volatile
Total Current Liabilities93.2 M88.8 M27.1 M
Slightly volatile
Property Plant And Equipment Net140.8 M134.1 M26.4 M
Slightly volatile
Accounts Payable3.3 M5 M3 M
Slightly volatile
Non Current Assets Total148.8 M141.8 M39.9 M
Slightly volatile
Net Receivables29.1 M27.7 M7 M
Slightly volatile
Common Stock Shares Outstanding173 M164.7 M77.2 M
Slightly volatile
Liabilities And Stockholders Equity661.8 M630.3 M260.4 M
Slightly volatile
Non Current Liabilities Total112.2 M106.9 M31.4 M
Slightly volatile
Other Current Assets12.7 M12.1 M5.8 M
Slightly volatile
Other Stockholder Equity66.4 M108.7 M54.2 M
Pretty Stable
Total Liabilities205.4 M195.6 M58.5 M
Slightly volatile
Property Plant And Equipment Gross143.1 M136.2 M26.8 M
Slightly volatile
Total Current Assets512.9 M488.5 M220.5 M
Slightly volatile
Short Term Debt51.3 M48.9 M10.7 M
Slightly volatile
Intangible Assets7 M5.7 M9.9 M
Pretty Stable
Cash66.4 M56.2 M89.9 M
Slightly volatile
Cash And Short Term Investments423.2 M403.1 M195.9 M
Slightly volatile
Common Stock1.4 B1.4 B661.8 M
Slightly volatile
Property Plant Equipment8.1 M7.7 M3.1 M
Slightly volatile
Capital Surpluse71.3 M67.9 M33.8 M
Slightly volatile
Non Current Liabilities Other8.8 M12.5 M6.6 M
Slightly volatile
Net Invested Capital349.2 M434.6 M260.4 M
Slightly volatile
Net Working Capital345.8 M399.8 M257.2 M
Slightly volatile
Capital Stock1.1 B1.4 B767.7 M
Slightly volatile
Capital Lease Obligations117.9 M112.2 M27.3 M
Slightly volatile

Aurinia Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization14.1 M13.4 M3.6 M
Slightly volatile
Selling General Administrative235.5 M224.3 M74.8 M
Slightly volatile
Total Revenue211.9 M201.8 M51.9 M
Slightly volatile
Other Operating Expenses322.6 M307.3 M111.8 M
Slightly volatile
Research Development59.9 M57.1 M30.8 M
Slightly volatile
Cost Of Revenue17.1 M16.3 M12.5 M
Slightly volatile
Total Operating Expenses305.6 M291 M108.4 M
Slightly volatile
Interest Income18.5 M17.6 M6 M
Slightly volatile
Net Interest Income16.8 M16 M3.7 M
Slightly volatile
Reconciled Depreciation8.4 M8 M2.8 M
Slightly volatile
Non Operating Income Net Other818 K476.1 K1.2 M
Slightly volatile

Aurinia Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow62 M108.3 M90.1 M
Slightly volatile
Depreciation14.1 M13.4 M3.6 M
Slightly volatile
Capital Expenditures1 M825.7 K843.7 K
Pretty Stable
Stock Based Compensation54.7 M52.1 M16.2 M
Slightly volatile
Cash Flows Other Operating7.1 M4.8 M10.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.276.6586
Very volatile
Days Sales Outstanding69.5245.09117
Very volatile
Average Payables841.8 K886.1 K757.6 K
Slightly volatile
Stock Based Compensation To Revenue0.220.235.0373
Very volatile
Capex To Depreciation0.06730.07090.52
Very volatile
EV To Sales6.516.85463
Very volatile
Days Of Inventory On Hand511922712
Slightly volatile
Payables Turnover2.22.943.5868
Slightly volatile
Sales General And Administrative To Revenue1.211.2814.6699
Very volatile
Research And Ddevelopement To Revenue0.240.2533.3096
Very volatile
Capex To Revenue0.00450.00470.1843
Slightly volatile
Cash Per Share2.672.812.1382
Slightly volatile
Days Payables Outstanding95.4410048.8 K
Slightly volatile
Income Quality0.470.490.7596
Slightly volatile
Intangibles To Total Assets0.00780.00820.219
Slightly volatile
Current Ratio6.984.959.1702
Slightly volatile
Receivables Turnover9.78.386.5809
Pretty Stable
Graham Number6.216.546.602
Very volatile
Capex Per Share0.00550.00580.0455
Slightly volatile
Average Receivables157.7 K166.1 K155.5 K
Slightly volatile
Revenue Per Share1.741.410.6182
Pretty Stable
Interest Debt Per Share0.750.810.2088
Slightly volatile
Debt To Assets0.170.160.0566
Slightly volatile
Days Of Payables Outstanding95.4410048.8 K
Slightly volatile
Ebt Per Ebit0.80.761.0284
Pretty Stable
Quick Ratio6.854.499.0023
Slightly volatile
Net Income Per E B T1.061.160.9748
Slightly volatile
Cash Ratio0.540.576.3952
Very volatile
Days Of Inventory Outstanding511922712
Slightly volatile
Days Of Sales Outstanding69.5245.09117
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.431.171.1066
Very volatile
Fixed Asset Turnover1.291.3610.8577
Slightly volatile
Debt Ratio0.170.160.0566
Slightly volatile
Price Sales Ratio6.276.6586
Very volatile
Asset Turnover0.210.370.2178
Pretty Stable

Aurinia Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1.3 B
Slightly volatile
Enterprise Value1.5 B1.4 B1.1 B
Slightly volatile

Aurinia Fundamental Market Drivers

Forward Price Earnings11.6144
Cash And Short Term Investments350.5 M

Aurinia Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aurinia Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Aurinia Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Aurinia Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue5.5 M3.5 M
Total Revenue201.8 M211.9 M
Cost Of Revenue16.3 M17.1 M
Stock Based Compensation To Revenue 0.23  0.22 
Sales General And Administrative To Revenue 1.28  1.21 
Research And Ddevelopement To Revenue 0.25  0.24 
Revenue Per Share 1.41  1.74 
Ebit Per Revenue(0.60)(0.63)

Currently Active Assets on Macroaxis

EBRCentrais Electricas Brasileiras
HEHawaiian Electric Industries
VFCVF Corporation
BVHMFVistry Group PLC
SSentinelOne
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:
How To Invest In Aurinia
Details
Is Aurinia Stock a good investment?
Details
What is Aurinia Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Aurinia Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
1.536
Quarterly Revenue Growth
0.243
Return On Assets
(0.02)
Return On Equity
(0.06)
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY